文献速递血栓与止血

罗米司亭作为原发性免疫性血小板减少症二线策略的免疫调节作用:iROM研究

Immunomodulation with romiplostim as a second-line strategy in primary immune thrombocytopenia: The iROM study.
PubMed 文献 · Br J Haematol · 2023-01-01

iROM研究纳入13例既往接受一线治疗的原发性免疫性血小板减少症患者,接受罗米司亭治疗22周并随访至52周。6例新诊断患者实现计划停药后的持续缓解,7例复发;持续缓解者罗米司亭剂量滴定更低、血小板反应更强,所有患者调节性T淋巴细胞计数升高,IL-4、IL-9和IL-17F水平显著下降。罗米司亭可调节免疫系统并可能影响ITP预后。

要点

  • 13例患者接受罗米司亭22周后随访至52周,6例新诊断ITP实现计划停药持续缓解,7例复发。
  • 持续缓解者罗米司亭剂量滴定更低、血小板计数反应更强,调节性T淋巴细胞计数更高。
  • 所有患者IL-4、IL-9和IL-17F水平显著下降,持续缓解者FOXP3、GATA3 mRNA表达及TGF-β水平升高。

核心结论

  • 罗米司亭治疗可调节免疫系统并可能影响ITP预后。
  • 血小板计数快速升高可能对诱导免疫耐受很重要。
  • 在自身免疫早期可能获得更好结局,但需临床研究确认。

研究设计与样本

  • iROM研究:13例既往接受一线治疗的原发性免疫性血小板减少症患者,中位年龄31岁,接受罗米司亭治疗22周并随访至52周。

主要发现

  • 6例新诊断ITP患者实现计划停用罗米司亭及持续停药缓解,其余7例复发。
  • 持续缓解者罗米司亭剂量滴定低于复发者,血小板计数反应强于复发者。
  • 所有患者调节性T淋巴细胞计数升高至研究完成,且持续缓解者计数更高。
  • 所有患者IL-4、IL-9和IL-17F水平显著下降。
  • 持续缓解者FOXP3(Treg)和GATA3(Th2)mRNA表达及转化生长因子-β水平升高。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Thrombopoietin receptor agonists (TPO-RAs) stimulate platelet production, which might restore immunological tolerance in primary immune thrombocytopenia (ITP). The iROM study investigated romiplostim's immunomodulatory effects. Thirteen patients (median age, 31 years) who previously received first-line treatment received romiplostim for 22 weeks, followed by monitoring until week 52. In addition to immunological data, secondary end-points included the sustained remission off-treatment (SROT) rate at 1 year, romiplostim dose, platelet count and bleedings. Scheduled discontinuation of romiplostim and SROT were achieved in six patients with newly diagnosed ITP, whereas the remaining seven patients relapsed. Romiplostim dose titration was lower and platelet count response was stronger in patients with SROT than in relapsed patients. In all patients, regulatory T lymphocyte (Treg) counts increased until study completion and the counts were higher in patients with SROT. Interleukin (IL)-4, IL-9 and IL-17F levels decreased significantly in all patients. FOXP3 (Treg), GATA3 (Th2) mRNA expression and transforming growth factor-β levels increased in patients with SROT. Treatment with romiplostim modulates the immune system and possibly influences ITP prognosis. A rapid increase in platelet counts is likely important for inducing immune tolerance. Better outcomes might be achieved at an early stage of autoimmunity, but clinical studies are needed for confirmation.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Schifferli A, Rüfer A, Rovo A, et al. Immunomodulation with romiplostim as a second-line strategy in primary immune thrombocytopenia: The iROM study. Br J Haematol. 2023. PMID: 37735543. doi:10.1111/bjh.19074

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。